GLYCAR T cells / Baylor College of Medicine - LARVOL DELTA

Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: Baylor College of Medicine | Active, not recruiting ➔ Completed | Trial completion date: Oct 2036 ➔ Jan 2023

Trial completion • Trial completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: Baylor College of Medicine | Recruiting ➔ Active, not recruiting | N=14 ➔ 9

Enrollment change • Enrollment closed • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

A Phase I clinical trial using armored GPC3 CART cells for children with relapsed/refractory liver tumors. (ASCO 2019) - P1; "Cohort 1 of this study is now open for enrollment. Clinical trial information: NCT02932956"

CAR T-Cell Therapy • Clinical • IO Biomarker • P1 data

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Baylor College of Medicine

Clinical • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liposarcoma • Liver Cancer • Nephrology • Oncology • Pediatrics • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Baylor College of Medicine; Trial completion date: Jul 2039 ➔ Jan 2040; Initiation date: Jul 2020 ➔ Jan 2021; Trial primary completion date: Aug 2024 ➔ Feb 2025

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liposarcoma • Liver Cancer • Nephrology • Oncology • Pediatrics • Rhabdoid Tumor • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Wilms Tumor

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Baylor College of Medicine; N=60 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Gastrointestinal Cancer • Hepatoblastoma • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

A Phase 1 Clinical Trial Using Armored GPC3-Car T Cells for Children with Relapsed/ Refractory Liver Tumors (ASGCT 2020) - P1 | "The initial results from this clinical trial show that GPC3-CAR T cells are well tolerated and have anti-tumor activity in children with liver tumors."

CAR T-Cell Therapy • Clinical • IO Biomarker • P1 data • CD8 • GPC3

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Baylor College of Medicine

Clinical • New P1 trial

ARMORED GPC3 CAR T CELLS FOR CHILDREN WITH RELAPSED/REFRACTORY LIVER TUMORS (SIOP 2019) - P1; "Our results indicate that the co-expression of IL-21 and IL-15 enhances the antitumor properties of GPC3-CAR T cells. Based on these results, we are now recruiting children in Cohort 1 of a Phase 1 trial to evaluate the safety, expansion, persistence and antitumor activity of GPC3-CAR T cells in children with liver cancers (GAP; NCT02932956)."

CAR T-Cell Therapy • Clinical • IO Biomarker

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Baylor College of Medicine

Clinical • New P1 trial

Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (clinicaltrials.gov) - P1; N=14; Recruiting; Sponsor: Baylor College of Medicine; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open